Wall Street analysts predict that Tabula Rasa HealthCare Inc (NASDAQ:TRHC) will post sales of $39.06 million for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Tabula Rasa HealthCare’s earnings, with the lowest sales estimate coming in at $38.70 million and the highest estimate coming in at $39.62 million. Tabula Rasa HealthCare reported sales of $27.31 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 43%. The firm is scheduled to report its next earnings results on Monday, March 12th.
According to Zacks, analysts expect that Tabula Rasa HealthCare will report full-year sales of $39.06 million for the current financial year, with estimates ranging from $127.30 million to $130.24 million. For the next year, analysts expect that the firm will post sales of $179.64 million per share, with estimates ranging from $174.90 million to $182.90 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover Tabula Rasa HealthCare.
Tabula Rasa HealthCare (NASDAQ:TRHC) last posted its earnings results on Monday, November 6th. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.02. Tabula Rasa HealthCare had a negative net margin of 2.27% and a negative return on equity of 5.58%. The firm had revenue of $33.27 million during the quarter, compared to analysts’ expectations of $31.76 million. During the same quarter in the prior year, the business earned $0.06 earnings per share. The business’s revenue for the quarter was up 37.6% compared to the same quarter last year.
Several research analysts have recently issued reports on the company. BidaskClub raised Tabula Rasa HealthCare from a “hold” rating to a “buy” rating in a research note on Thursday, December 21st. Oppenheimer assumed coverage on Tabula Rasa HealthCare in a research note on Monday, December 18th. They issued an “outperform” rating and a $35.00 price objective for the company. William Blair assumed coverage on Tabula Rasa HealthCare in a research note on Monday, December 11th. They issued an “outperform” rating for the company. Zacks Investment Research downgraded Tabula Rasa HealthCare from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 10th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $35.00 price objective on shares of Tabula Rasa HealthCare in a research note on Tuesday, November 7th. They noted that the move was a valuation call. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $29.00.
Tabula Rasa HealthCare (TRHC) traded down $0.35 during trading on Friday, hitting $28.54. The stock had a trading volume of 79,900 shares, compared to its average volume of 109,672. Tabula Rasa HealthCare has a one year low of $11.59 and a one year high of $36.80. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.73 and a quick ratio of 0.66. The firm has a market capitalization of $515.66, a P/E ratio of -114.16, a P/E/G ratio of 38.52 and a beta of 2.81.
In other Tabula Rasa HealthCare news, major shareholder Growth Fund 1Q Lp Originate sold 684,180 shares of the stock in a transaction that occurred on Monday, December 11th. The shares were sold at an average price of $25.85, for a total transaction of $17,686,053.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Orsula V. Knowlton sold 8,000 shares of the stock in a transaction that occurred on Wednesday, October 18th. The shares were sold at an average price of $26.68, for a total transaction of $213,440.00. The disclosure for this sale can be found here. Insiders have sold a total of 1,099,180 shares of company stock valued at $28,435,203 in the last three months. Insiders own 45.80% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the business. Hood River Capital Management LLC increased its position in Tabula Rasa HealthCare by 7.5% during the 2nd quarter. Hood River Capital Management LLC now owns 825,225 shares of the company’s stock valued at $12,420,000 after purchasing an additional 57,724 shares during the period. Vanguard Group Inc. increased its position in Tabula Rasa HealthCare by 13.4% during the 2nd quarter. Vanguard Group Inc. now owns 236,964 shares of the company’s stock valued at $3,566,000 after purchasing an additional 27,997 shares during the period. Pier Capital LLC acquired a new stake in Tabula Rasa HealthCare during the 3rd quarter valued at approximately $4,151,000. Wasatch Advisors Inc. acquired a new stake in Tabula Rasa HealthCare during the 3rd quarter valued at approximately $4,047,000. Finally, EAM Investors LLC acquired a new stake in Tabula Rasa HealthCare during the 3rd quarter valued at approximately $3,931,000. 31.85% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This article was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/13/39-06-million-in-sales-expected-for-tabula-rasa-healthcare-inc-trhc-this-quarter.html.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.
Get a free copy of the Zacks research report on Tabula Rasa HealthCare (TRHC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.